


BMJ Open Impact of stroke severity on aspiration pneumonia risks in the medical ward versus the stroke unit: a 10-year retrospective cohort study

Kim H Tran ¹, Naveed Akhtar,² Aizaz Ali,³ Sujata Joseph,² Deborah Morgan,² Blessy Babu,² Ryan Ty Uy,² Ashfaq Shuaib¹

To cite: Tran KH, Akhtar N, Ali A, *et al.* Impact of stroke severity on aspiration pneumonia risks in the medical ward versus the stroke unit: a 10-year retrospective cohort study. *BMJ Open* 2025;**15**:e093328. doi:10.1136/bmjopen-2024-093328

► Prepublication history and additional supplemental material for this paper are available online. To view these files, please visit the journal online (<https://doi.org/10.1136/bmjopen-2024-093328>).

Received 04 September 2024
Accepted 28 February 2025



© Author(s) (or their employer(s)) 2025. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ Group.

¹Department of Neurology, University of Alberta, Edmonton, Alberta, Canada

²Department of Neuroscience, Hamad Medical Corporation, Doha, Qatar

³Department of Neurology, University of Toledo, Toledo, Ohio, USA

Correspondence to

Dr Ashfaq Shuaib;
shuaib@ualberta.ca

ABSTRACT

Objective Aspiration pneumonia is a common complication post-stroke that increases the patient's duration of stay in hospital, mortality and morbidity. We examined the incidence, clinical characteristics and outcomes among ischaemic stroke-related aspiration pneumonia patients in Qatar.

Settings and participants The Qatar Stroke database was reviewed for patients with acute ischaemic stroke admitted to Hamad General Hospital, a tertiary care medical facility, between January 2014 and April 2024.

Outcomes Patients were retrospectively assessed for mortality at 90 days, modified Rankin Score at 90 days and length of stay. Several clinical characteristics were also compared between patients with acute ischaemic stroke who developed aspiration pneumonia versus those without.

Results Patients with stroke who developed aspiration pneumonia tended to be older and of the male sex. Patients who developed aspiration pneumonia were also more likely to present with a higher National Institute of Health Stroke Scale (NIHSS) at admission ($p<0.001$). Patients with large vessel disease, cardioembolic stroke, stroke of determined aetiology and stroke of undetermined aetiology were more likely to develop aspiration pneumonia. They also stayed an average of 10 days longer in the hospital compared with patients without aspiration pneumonia (16.0 vs 5.3 days). Patients admitted to the medicine ward had higher odds of developing aspiration pneumonia in contrast to patients admitted to the stroke ward (adjusted OR of 1.56, 95% CI: 1.05 to 2.31). Patients with aspiration pneumonia had unfavourable outcomes (modified Rankin Scale 3–6) at 90 days (74.6% vs 30.4% for an NIHSS admission score of 5–9 and 79.6% vs 59.5% for an NIHSS admission >10). They were also more likely to have higher mortality rates at 90 days (16.9% vs 1.9% for an NIHSS admission score of 5–9 and 22.3% vs 13.8% for an NIHSS admission score >10) and major adverse cardiovascular events at 1 year (23.7% vs 3.8% for an NIHSS admission score of 5–9 and 27.5% vs 16.2% for NIHSS >10).

Conclusion Age, sex, admission NIHSS severity, stroke subtypes and admission location are independent predictors of aspiration pneumonia post-stroke.

STRENGTHS AND LIMITATIONS OF THIS STUDY

- ⇒ This study is based on a large stroke registry with 9197 patients with acute ischaemic stroke enrolled over a 10-year period.
- ⇒ Our patient sample is comprised of largely Middle Eastern ethnicity, South Asian and Far Eastern, therefore lacks generalisability.

INTRODUCTION

Stroke is a major cause of death and disability worldwide. Early in the course of the disease, patients with stroke are at risk for medical complications including dysphagia and aspiration pneumonia.¹ Dysphagia is characterised by difficulty swallowing due to weakness/reduced coordination between facial, palatal and pharyngeal muscles (due to reduced cortical connectivity between neural regions post-stroke).² The incidence of dysphagia after stroke ranges from 8.1% to 80%,^{3–7} it is frequently silent and it is highly associated with aspiration pneumonia.⁸ Dysphagia causes oral or gastric contents to enter the lung, which suppresses the natural defences of the respiratory system, increasing the risks for opportunistic infections.^{9–11} Several studies have identified multiple risk factors associated with aspiration pneumonia, such as reduced level of consciousness, incorrect postures and advanced age.^{12–15}

Pneumonia is one of the leading causes of mortality for acute stroke, with a 30-day mortality rate of up to 30%.¹⁶ Aspiration pneumonia also increases the risk of prolonged hospital stay and poor prognosis.¹⁷ Animal and clinical studies have demonstrated that silent aspiration (micro-aspiration due to dysphagia during the night) is the primary cause of aspiration pneumonia.¹⁸ Despite different preventative and therapeutic approaches for managing patients with

aspiration pneumonia, its incidence and mortality rates remain high.¹⁹ For example, in a case-control study comprising 1 112 944 patients, Gupte *et al*²⁰ reported that aspiration pneumonia due to cerebrovascular disease accounted for 11.7% of deaths in the USA (62 068 deaths per year from 1999 to 2017), with increasing mortality rates since 2009. In countries such as Egypt and Brazil, the incidence of aspiration pneumonia can be as high as 44% and 76%, respectively.^{19 21}

There are very few studies on the incidence, causes and outcomes of aspiration pneumonia from the Middle East and North Africa (MENA) region.²² This study aimed to assess the clinical characteristics and treatment outcomes among stroke-related aspiration pneumonia patients in Qatar.

METHODS

Data from patients admitted with a stroke to Hamad General Hospital (HGH), Doha, Qatar, from January 2014 through April 2024 were analysed from a hospital-based prospective stroke registry. HGH is a Joint Commission International accredited 600-bed hospital, with 200 beds reserved for medical patients. It is the only tertiary care medical facility in Qatar where the stroke service is located, 95% of all strokes in Qatar requiring admission to hospital are admitted to HGH. The programme provides 24-hour thrombolysis and thrombectomy services for acute stroke management. Patients are evaluated by the stroke team in the emergency department (ED), and urgent decisions about treatment are made. Patients with hyperacute stroke are admitted to a dedicated 12-bed stroke unit or medical intensive care unit as necessary. Non-urgent patients with stroke are admitted under the medical team, with neurology consultation in the ED. HGH has the required laboratory, neuroradiological and neurosurgical infrastructure to manage patients with stroke effectively. The stroke team is readily available to make immediate treatment decisions for acute stroke cases.

Study variables

The primary outcome variables were duration of stay in the ED, length of stay (LOS), modified Rankin Score at 90 days and mortality at 90 days.

The independent variables were age, sex, development of post-stroke pneumonia and admission location (stroke ward vs medical ward).

Patient characteristics

Patient characteristics including age, sex, ethnicity, medical comorbidities and prior medication were collected in the HGH Stroke Registry. National Institute of Health Stroke Scale (NIHSS) score, neuroimaging data and post-discharge disposition were entered into the registry as well. Ischaemic stroke was diagnosed according to the WHO criteria²³ and stroke subtypes were defined by the Trial of Org 10172 in Acute Stroke

Treatment (TOAST) criteria.²⁴ The modified Rankin Scale (mRS) measurements were done at discharge and at 90 days following onset of symptoms. The patients were classified as favourable (mRS ≤ 2) or unfavourable (mRS 3–6) outcome. We used the dichotomised mRS scale to evaluate recovery at 90 days.²⁵ The NIHSS score was developed by the National Institutes of Health and is widely referenced in clinical settings for stroke assessment. The tool is highly regarded for its reliability and ability to track neurological changes over time.²⁶ The mRS is a widely used tool to assess the degree of disability or dependence in individuals who have suffered a stroke or other neurological events. It measures the functional outcome of a patient after a neurological injury, such as a stroke, and evaluates the level of independence in daily activities.²⁷

Diabetes was diagnosed according to the American Diabetes Association (ADA) and WHO recommendation²⁸ and included patients with a previous diagnosis of diabetes, on medication for diabetes or a hemoglobin A1c (HbA1c; marker for the average of blood glucose levels over the preceding 2–3 months) of more than 6.5% and the diagnosis of pre-diabetes was based on an HbA1c of 5.7–6.4% as per the 2015 ADA clinical practice recommendations. Hypertension was defined as systolic blood pressure ≥ 140 mm Hg or a diastolic pressure ≥ 90 mm Hg, or on current treatment with antihypertensive drugs. Dyslipidaemia was defined as low-density lipoprotein-cholesterol level ≥ 3.62 mmol/L, high-density lipoprotein cholesterol level ≤ 1.03 mmol/L, triglycerides ≥ 1.69 mmol/L or current treatment with a cholesterol-lowering drug.

Data collection and inclusion/exclusion criteria

Patients' data were collected by trained stroke clinical nurse specialists. Their data were then identified and confirmed using the International Classification of Disease (ICD), 10th edition's definitions (H34.1, 163.x, 164.x, 161.x, 160.x, G45.x). For our study, we only included patients diagnosed with acute ischaemic stroke and excluded patients diagnosed with intracerebral haemorrhage, transient ischaemic attacks, stroke mimics and cerebral venous thrombosis. Clinical diagnosis (via assessing symptoms like fever, cough, dyspnoea and purulent sputum) and/or radiological imaging (CT and chest X-rays to identify lung consolidation or infiltrates indicative of pneumonia) were used to confirm the diagnosis of post-stroke aspiration pneumonia. Microbiological testing including sputum culture, blood cultures and bronchoalveolar lavage were also performed when clinical or imaging diagnoses were inconclusive. The methods used are consistent with current guidelines.^{29 30}

Patient and public involvement

Patients or the public were not involved in the design, or conduct, or reporting, or dissemination plans of our research.

Data quality control

Data quality control in the HGH Stroke Registry was ensured through several key practices. Stroke coordinators received training on data collection and ICD-10 coding, and standardised procedures are followed to maintain consistency. Diagnoses were confirmed using ICD-10 codes, and registry entries are cross-checked with patient records to ensure accuracy. Automated tools flag errors, and manual reviews ensure corrections are made when necessary. Routine audits and continuous monitoring of data help identify and correct errors, maintaining the integrity of the registry. These measures help ensure high-quality, reliable data for stroke care analysis and improvement.

Data analysis and statistics

Descriptive results for all continuous variables were reported as mean±SD for normally distributed data or median with range for data with non-normal distributions. The distribution of continuous variables was assessed before using statistical tools. Mean level comparisons between patients with aspiration pneumonia versus without aspiration pneumonia were assessed using analysis of variance (ANOVA) test and multiple comparisons were performed using Bonferroni correction. If an assumption of an ANOVA test was failed, then an alternative non-parametric Kruskal-Wallis test was performed. Pearson χ^2 test and Fisher's exact test were performed whenever appropriate to compare the proportion of all categorical variables between the groups. Multiple logistic regression analysis was performed to assess for risk factors associated with aspiration pneumonia after selecting important and significant variables at univariate analysis. Odds ratio (OR) and the 95% CI for the OR were reported. A p value of ≤0.05 (two-tailed) was considered significant. SPSS statistical package V.29.0.1.0 was used for the analysis.

RESULTS

Patient characteristics

A total of 9197 patients were enrolled: 380 developed aspiration pneumonia (4.1%) during hospitalisation while 8817 (95.9%) of the patients did not have pneumonia. The mean age of patients was 55.3±13.4 years, with patients with aspiration pneumonia being significantly older than healthy controls ($p<0.001$). 80% were men, 57% had diabetes mellitus, 72% had hypertension, 46% had dyslipidaemia and 24% were active smokers. The high proportion of men is reflective of the very high male expatriate population as previously reported.³¹ A summary of patients' baseline characteristics is outlined in [table 1](#).

Since 95.9% of our patients did not have aspiration pneumonia, we performed subanalyses on clinical outcomes based on patients' admission NIHSS

scores. Subanalyses were performed for patients with an NIHSS of 5–9 (moderate stroke) and NIHSS>10 (severe stroke) ([table 2](#)).

Mode of transport

Mode of transport was significantly associated with aspiration pneumonia risks ($p<0.001$). However, this was only significant for emergency medical services (EMS) versus non-medical services ($p<0.001$), with a higher proportion of patients developing aspiration pneumonia via EMS (4.5%) versus non-medical services (1.5%). Patients transported with EMS had a significantly higher NIHSS at admission (5.9±6.1 vs 3.3±3.7, $p<0.001$). The total sample size for EMS was 6361 versus 2234 for non-medical services.

Onset duration

Duration of stroke symptoms from the time of onset to evaluation was significantly associated with aspiration pneumonia ($p<0.001$). This was only significant for <4.5 hours versus >24 hours ($p<0.001$) and 4.5–24 hours versus >24 hours ($p<0.001$). A stroke onset to emergency evaluation of <4.5 hours had the highest proportion of aspiration pneumonia (5.7%) versus 4.8% for onset duration of 4.5–24 hours and 2.1% for >24 hours (online supplemental table S1).

Duration of stay in the emergency department

Duration of stay in the ED was not significantly associated with aspiration pneumonia ($p=0.11$) (online supplemental table S1). Furthermore, when we analysed duration of stay in the ED based on NIHSS scores (5–9 and >10), duration of stay in the ED remained non-significant ($p=0.052$ and 0.09), respectively ([table 2](#)).

Stroke diagnosis

Stroke diagnosis is shown in online supplemental table S1. Overall, type of stroke was significantly associated with aspiration pneumonia ($p<0.001$). Further analyses revealed that the risk of developing aspiration pneumonia was not significantly different between large vessel disease versus cardioembolic stroke ($p=1.00$), large vessel disease versus stroke of undetermined aetiology ($p=1.00$), cardioembolic stroke versus stroke of determined aetiology ($p=0.06$), cardioembolic stroke versus stroke of undetermined aetiology ($p=1.00$) and stroke of determined aetiology versus stroke of undetermined aetiology ($p=0.82$).

Patients with small vessel disease had the lowest proportions of aspiration pneumonia (0.8%) compared with large vessel disease (7.4%), cardioembolic stroke (7.3%), stroke of determined aetiology (4.8%) and stroke of undetermined aetiology (6.8%), $p<0.001$ ([table 3](#)).

Admission NIHSS score

Admission NIHSS score was significantly associated with aspiration pneumonia ($p<0.001$). Fisher's exact test revealed that there was a significant association between aspiration pneumonia for patients with an NIHSS score of 0–4 ($p=0.03$), and NIHSS score of >10, $p<0.001$ (online

Table 1 Characteristics and outcome of patients with acute ischaemic stroke with aspiration pneumonia

Characteristic	No pneumonia (n=8817, 95.9%)	Aspiration pneumonia (n=380, 4.1%)	Total (n=9197)	P value
Age	55.1±13.3	59.0±15.6	55.3±13.4	<0.001
Male gender	7041 (79.9)	303 (79.7)	7344 (79.9)	0.95
Diabetes	5038 (57.1)	229 (60.3)	5267 (57.3)	0.22
Hypertension	6373 (72.3)	246 (64.7)	6619 (72.0)	<0.001
Dyslipidaemia	4069 (46.1)	136 (35.8)	4205 (45.7)	<0.001
Prior stroke or TIA	1156 (13.1)	63 (16.6)	1219 (13.3)	0.05
Coronary artery disease	1053 (11.9)	70 (18.4)	1123 (12.2)	<0.001
Atrial fibrillation	664 (7.5)	73 (19.2)	737 (8.0)	<0.001
Active smoking	2143 (24.3)	52 (13.7)	2195 (23.9)	<0.001
Ethnicity*				
Arab	2962 (33.6)	160 (42.1)	3122 (33.9)	<0.001
South Asian	4518 (51.2)	168 (44.2)	4686 (51.0)	
Far Eastern	753 (8.5)	17 (4.5)	770 (8.4)	
African	382 (4.3)	26 (6.8)	408 (4.4)	
Caucasian	202 (2.3)	9 (2.4)	211 (2.3)	
Mode of arrival*				
EMS	6073 (68.9)	288 (75.8)	6361 (69.2)	<0.001
Non-medical	2200 (25.0)	34 (8.9)	2234 (24.3)	
From other hospitals	372 (4.2)	15 (3.9)	387 (4.2)	
mRS prior to acute stroke*				
0	7595 (86.1)	282 (74.2)	7877 (85.6)	<0.001
1	132 (1.5)	9 (2.4)	141 (1.5)	
2	312 (3.5)	12 (3.2)	324 (3.5)	
3	430 (4.9)	33 (8.7)	463 (5.0)	
4	196 (2.2)	23 (6.1)	219 (2.4)	
5	151 (1.7)	21 (5.5)	172 (1.9)	
NIHSS on admission	5.1±5.54	14.65±8.05	5.5±6.0	<0.001
Onset duration*				
Less than 4.5 hours	2822 (32.0)	169 (44.5)	2991 (32.5)	<0.001
Between 4.5 hours and 24 hours	2890 (32.8)	145 (38.2)	3035 (33.0)	
More than 24 hours	3105 (35.2)	66 (17.4)	3171 (34.5)	
Thrombolysis given	962 (10.9)	73 (19.2)	1035 (11.3)	<0.001
Mechanical thrombectomy done	350 (4.0)	43 (11.3)	393 (4.3)	<0.001
BMI on admission	28.15±43.9	27.54±5.3	28.13±43.0	0.8
RBS on admission	9.6±7.5	10.4±5.05	9.6±7.4	0.04
HbA1c	7.51±2.42	7.6±2.4	7.51±2.41	0.64
Serum cholesterol	4.84±1.52	4.6±1.75	4.83±1.53	0.01
Serum triglyceride	1.8±1.76	1.45±0.83	1.77±1.73	0.002
Serum HDL	1.1±3.24	1.43±6.34	1.10±3.38	0.12
Serum LDL	3.1±1.8	2.82±1.25	3.1±1.8	0.03
Systolic blood pressure	157.8±44.23	149.44±29.15	157.42±43.73	0.00
Diastolic blood pressure	91.1±22.4	86.4±19.4	90.9±22.3	0.00
Length of stay	5.25±8.55	16.0±14.93	5.70±9.2	0.00

Continued

Table 1 Continued

Characteristic	No pneumonia (n=8817, 95.9%)	Aspiration pneumonia (n=380, 4.1%)	Total (n=9197)	P value
Disposition*				
Discharged home	5726 (64.9)	44 (11.6)	5770 (62.7)	<0.001
Rehabilitation	2079 (23.6)	89 (23.4)	2168 (23.6)	
Long-term care	151 (1.7)	97 (25.5)	248 (2.7)	
Transfer to another facility	732 (8.3)	109 (28.7)	841 (9.1)	
Died as an inpatient	129 (1.5)	41 (10.8)	170 (1.8)	
TOAST classification*				
Small vessel disease	4213 (47.8)	36 (9.5)	4249 (46.2)	<0.001
Large vessel disease	1772 (20.1)	141 (37.1)	1913 (20.8)	
Cardioembolic	1744 (19.8)	137 (36.1)	1881 (20.5)	
Stroke of determined aetiology	612 (6.9)	31 (8.2)	643 (7.0)	
Stroke of undetermined aetiology	476 (5.4)	35 (9.2)	511 (5.6)	
Swallow screen done before oral intake	5820 (66.0)	197 (51.8)	6017 (65.4)	<0.001
Speech therapy assessment done	6024 (68.3)	161 (42.4)	6185 (67.3)	<0.001
Speech therapy assessment duration (hours)	31.7±309.7	77.9±694.32	32.85±325.45	0.07
Antibiotics given	626 (7.1)	361 (95.0)	987 (10.7)	<0.001

Values are reported as mean±SD and n (%).

*p value reported based on Pearson χ^2 test or Fisher's exact test, whenever appropriate.

BMI, body mass index; EMS, emergency medical services; HbA1C, Hemoglobin A1C; HDL, high density lipoprotein; ICU, intensive care unit; LDL, Low density lipoprotein; mRS, modified Rankin Scale; NIHSS, National Institute of Health Stroke Scale; RBS, random blood sugar; TIA, Transient Ischemic Attack; TOAST, Trial of Org 10172 in Acute Stroke Treatment.

supplemental table S2). Patients with an NIHSS>10 had the highest proportion of aspiration pneumonia (16.5%). Moreover, patients with an NIHSS>10 and concomitant aspiration pneumonia had higher rates of mortality at 90 days (22.3%) when compared with patients with an NIHSS score of 5–9 and concomitant aspiration pneumonia (16.9%) ($p<0.001$) (table 2). In patients with aspiration pneumonia, patients with an NIHSS>10 also had higher rates of major adverse cardiovascular events (MACE) at 1-year compared with patients with an NIHSS of 5–9 (27.5% vs 23.7%, $p<0.001$).

Length of stay

Patients with aspiration pneumonia stayed an average of 10 days longer in the hospital compared with patients without aspiration pneumonia (16.0 days vs 5.3 days, $p=0.00$). When analysed via admission NIHSS severity, patients with aspiration pneumonia stayed significantly longer in the hospital compared with those without aspiration pneumonia (17.1 days vs 5.9 days, $p<0.001$ for NIHSS of 5–9 and 16.6 days vs 9.2 days, $p<0.001$ for NIHSS>10).

Admission location

Overall, 3966 (75.1%) patients were admitted to the stroke ward and 1318 (24.9%) patients were

admitted to the medical ward. A higher proportion of patients admitted to the medicine ward developed aspiration pneumonia in contrast to patients admitted to the stroke ward (5.3% vs 3.7%, $p=0.01$) (table 3). 2.3% of patients with an NIHSS of 0–4 and admitted to the medicine ward developed aspiration pneumonia compared with 1.2% of patients with an NIHSS of 0–4 and admitted to the stroke ward ($p=0.03$) (online supplemental table S2). Similarly, 19.9% of patients with an NIHSS>10 and admitted to the stroke ward developed aspiration pneumonia compared with 9.9% of patients with an NIHSS>10 and admitted to the stroke ward ($p<0.001$) (figure 1).

Modified Rankin Scale at 90 days

A higher proportion of patients with aspiration pneumonia had an unfavourable outcome (mRS 3–6) at 90 days compared with patients without aspiration pneumonia (74.6% vs 30.4% for NIHSS of 5–9), $p<0.001$ (table 2). Similar observations were seen for NIHSS>10 (79.6% vs 59.5%, $p<0.001$). Figures 2 and 3 illustrate the proportion of mRS at 90 days based on NIHSS admission scores.

Table 2 Characteristics and outcome of patients with acute ischaemic stroke with aspiration pneumonia based on their NIHSS admission

Characteristic or investigation	No pneumonia (n=8817, 95.9%)	Aspiration pneumonia (n=380, 4.1%)	Total (n=9197)	P value
NIHSS severity				
Mild stroke (NIHSS 0–4)	5570 (63.2)	56 (14.7)	5626 (61.2)	<0.001
Moderate stroke (NIHSS 5–9)	1906 (21.6)	59 (15.5)	1965 (21.4)	
Severe stroke (NIHSS 10 or more)	1341 (15.2)	265 (69.7)	1606 (17.5)	
NIHSS (5–9)				
90 days mortality	36 (1.9)	10 (16.9)	46 (2.3)	<0.001
MACE at 1 year	72 (3.8)	14 (23.7)	86 (4.4)	<0.001
Admission location				
Stroke ward	1281 (67.2)	35 (59.3)	1316 (67.0)	0.31
Medicine ward	250 (13.1)	10 (16.9)	45 (13.2)	
Duration of ED stay category ^a				
<4 hours	249 (13.1)	2 (3.4)	251 (12.8)	0.052
4–8 hours	555 (29.1)	23 (39.0)	578 (29.4)	
>8 hours	750 (39.3)	26 (44.1)	776 (39.5)	
Length of stay	5.89±10.0	17.1±19.4	6.23±10.5	<0.001
Prognosis—at discharge				
Good (mRS 0–2)	814 (42.7)	4 (6.8)	818 (41.6)	<0.001
Poor (mRS 3–6)	1092 (57.3)	55 (93.2)	1147 (58.4)	
Prognosis—at 90 days				
Good (mRS 0–2)	876 (46.0)	6 (10.2)	882 (44.9)	<0.001
Poor (mRS 3–6)	580 (30.4)	44 (74.6)	624 (31.8)	
Mortality at discharge	9 (0.5)	7 (11.9)	16 (0.8)	<0.001
90 days mortality	36 (1.9)	10 (16.9)	46 (2.3)	<0.001
mRS at 90 days ^a				
0	446 (23.4)	0 (0)	446 (22.7)	<0.001
1	212 (11.1)	3 (5.1)	215 (10.4)	
2	218 (11.4)	3 (5.1)	221 (11.2)	
3	325 (17.1)	6 (10.2)	331 (16.8)	
4	160 (8.4)	10 (16.9)	170 (8.7)	
5	59 (3.1)	18 (30.5)	77 (3.9)	
6	36 (1.9)	10 (16.9)	46 (2.3)	
NIHSS (>10)				
90 days mortality	185 (13.8)	59 (22.3)	244 (15.2)	0.003
MACE at 1 year	217 (16.2)	73 (27.5)	290 (18.1)	<0.001
Admission location				
Stroke ward	834 (62.2)	92 (34.7)	926 (57.7)	<0.001
Medicine ward	166 (12.4)	40 (15.1)	206 (12.8)	
Duration of ED stay category ^a				
<4 hours	288 (21.5)	41 (15.5)	329 (20.5)	0.09
4–8 hours	446 (33.3)	87 (32.8)	533 (33.2)	
>8 hours	470 (35.0)	103 (38.9)	573 (35.7)	
Length of stay	9.2±9.8	16.6±14.6	10.4±11.2	<0.001
Prognosis—at discharge				

Continued

Table 2 Continued

Characteristic or investigation	No pneumonia (n=8817, 95.9%)	Aspiration pneumonia (n=380, 4.1%)	Total (n=9197)	P value
Good (mRS 0–2)	247 (18.4)	5 (1.9)	252 (15.7)	<0.001
Poor (mRS 3–6)	1094 (81.6)	260 (98.1)	1354 (84.3)	
Prognosis—at 90 days				
Good (mRS 0–2)	301 (22.4)	18 (6.8)	319 (19.9)	<0.001
Poor (mRS 3–6)	798 (59.5)	211 (79.6)	1009 (62.8)	
Mortality at discharge	105 (7.8)	30 (11.3)	135 (8.4)	0.07
90 days mortality	185 (13.8)	59 (22.3)	244 (15.2)	<0.001
mRS at 90 days ^a				
0	132 (9.8)	5 (1.9)	137 (8.5)	<0.001
1	72 (5.4)	3 (1.1)	75 (4.7)	
2	97 (7.2)	10 (3.8)	107 (6.7)	
3	219 (16.3)	18 (6.8)	237 (14.8)	
4	223 (16.6)	46 (17.4)	269 (16.7)	
5	171 (12.8)	88 (33.2)	259 (16.1)	
6	185 (13.8)	59 (22.3)	244 (15.2)	

^ap value reported based on Pearson χ^2 test or Fisher's exact test, whenever appropriate.

ED, emergency department; MACE, major adverse cardiovascular event; mRS, modified Rankin Scale; NIHSS, National Institute of Health Stroke Scale.

Mortality at 90 days

For patients with an NIHSS score of 5–9, a higher proportion of patients with aspiration pneumonia died at 90 days (16.9%) compared with patients without aspiration pneumonia (1.9%), $p<0.001$. Similar observations were seen for NIHSS>10 (22.3% vs 13.8%, $p=0.003$).

Multivariate analysis for risk factors associated with aspiration pneumonia

Table 3 describes a multiple binary logistic regression model to identify significant independent factors associated with the development of aspiration pneumonia after selecting important and significant variables at bivariate analysis. Men were more likely than women to have aspiration pneumonia risks (adjusted OR (aOR) 1.56, 95% CI: 1.05 to 2.32, $p=0.03$). Age was significantly associated with aspiration pneumonia (aOR 1.02, 95% CI: 1.01 to 1.03, $p=0.002$), with patients with aspiration pneumonia being significantly older ($p<0.001$). Large vessel disease was significantly associated with aspiration pneumonia (aOR 4.11, 95% CI: 2.52 to 6.69, $p<0.001$). Similar observations were seen for cardioembolic stroke ($p<0.001$), stroke of determined aetiology ($p<0.001$) and stroke of undetermined aetiology ($p<0.001$), see table 3. Patients with an NIHSS score of 5–9 and >10 also had high odds of developing aspiration pneumonia (aOR of 1.87 and 5.98, respectively). Patients admitted to the medicine ward also had 1.56 times the odds of developing aspiration pneumonia compared with the stroke ward

(95% CI: 1.05 to 2.31, $p=0.03$). A forest plot of the multivariate analysis can be seen in figure 4.

DISCUSSION

To the best of our knowledge, this is the first study to specifically examine the incidence and outcomes of patients who develop aspiration pneumonia post-stroke in the MENA region. In our cohort, 4.1% of our patients developed aspiration pneumonia post stroke. This low number may be deceiving as the majority of patients admitted had mild symptoms (5626 (61.2%)) of patients had an NIHSS of <4). The odds of aspiration pneumonia were 1.87 in patients with admission NIHSS of 5–9 ($n=1965$), increasing to 5.98 in patients with NIHSS of 10 or more ($n=1606$). Patients with aspiration pneumonia also stayed an average of 10 days longer in the hospital compared with patients without. A higher proportion of patients with aspiration pneumonia had an unfavourable outcome at 90 days. They were also more likely to have higher mortality rates at 90 days and MACE at 1 year. Patients who were admitted to the medicine ward also had higher odds of developing aspiration pneumonia in contrast to patients admitted to the stroke ward.

High NIHSS has also been shown to be correlated with increased rates of dysphagia and aspiration pneumonia due to stroke severity.³² Patients with aspiration pneumonia in the Qatar data set had comparatively higher NIHSS at presentation as compared with patients without pneumonia (14.7 vs 5.1, $p<0.001$). Garavelli *et al*³³ demonstrated that an NIHSS cut-off of ≥ 10.5 was

Table 3 Bivariate and multivariate logistic regression analysis to identify the risk factors associated with aspiration pneumonia

Determinants			Bivariate logistic regression analysis			Multivariate logistic regression analysis		
	No pneumonia	Aspiration pneumonia	Standardised beta	OR (95% CI)	P value	Standardised beta	OR (95% CI)	P value
Age	55.3±13.4	59.0±15.6	0.021	1.02 (1.01 to 1.03)	<0.001	0.017	1.02 (1.01 to 1.03)	0.002
Sex								
Female	1776 (95.8)	77 (4.2)	–	1	–	–	1	–
Male	7041 (95.9)	303 (4.1)	–0.007	0.99 (0.77 to 1.28)	0.95	0.446	1.56 (1.05 to 2.32)	0.03
TOAST								
SVD	4213 (99.2)	36 (0.8)	–	1	–	–	1	–
LVD	1772 (92.6)	141 (7.4)	2.231	9.31 (6.43 to 13.48)	<0.001	1.413	4.11 (2.52 to 6.69)	<0.001
CE	1744 (92.7)	137 (7.3)	2.218	9.19 (6.34 to 13.33)	<0.001	1.306	3.69 (2.23 to 6.12)	<0.001
SDA	612 (95.2)	31 (4.8)	1.780	5.93 (3.64 to 9.65)	<0.001	1.179	3.25 (1.75 to 6.03)	<0.001
SUD	476 (93.2)	35 (6.8)	2.152	8.61 (5.35 to 13.83)	<0.001	1.408	4.09 (1.98 to 8.46)	<0.001
Mode of transport								
From other hospitals	372 (96.1)	15 (3.9)	–	1	–	–	1	–
EMS	6073 (95.5)	288 (4.5)	0.162	1.18 (0.69 to 2.00)	0.55	0.184	1.20 (0.55 to 2.64)	0.65
Non-medical	2200 (98.5)	34 (1.5)	–0.959	0.38 (0.21 to 0.71)	0.00	0.032	1.03 (0.43 to 2.47)	0.94
Onset duration								
<4.5 hours	2822 (94.3)	169 (5.7)	–	1	–	–	1	–
4.5–24 hours	3890 (96.4)	145 (3.6)	–0.177	0.84 (0.67 to 1.05)	<0.001	0.136	1.06 (0.68 to 1.65)	0.79
>24 hours	3105 (97.9)	66 (2.1)	–1.036	0.36 (0.27 to 0.47)	<0.001	0.061	1.15 (0.82 to 1.61)	0.43
Duration in ER								
<4 hours	809 (94.2)	50 (5.8)	–	1	–	–	1	–
4–8 hours	1711 (93.3)	122 (6.7)	0.143	1.15 (0.82 to 1.62)	0.41	0.343	1.41 (0.90 to 2.20)	0.13
>8 hours	2749 (94.8)	151 (5.2)	–0.118	0.89 (0.64 to 1.24)	0.48	0.217	1.24 (0.80 to 1.93)	0.34
NIHSS								
Mild stroke (0–4)	5570 (99.0)	56 (1.0)	–	1	–	–	1	–
Moderate stroke (5–14)	1906 (97.0)	59 (3.0)	1.125	3.08 (2.13 to 4.45)	<0.001	0.625	1.87 (1.19 to 2.94)	0.01
Severe stroke (>10)	1341 (83.5)	265 (16.5)	2.978	19.66 (14.64 to 26.38)	<0.001	1.788	5.98 (3.92 to 9.11)	<0.001
Admission location								
Stroke ward	3819 (96.3)	147 (3.7)	–	1	–	–	1	–
Medicine ward	1248 (94.7)	70 (5.3)	0.377	1.46 (1.09 to 1.95)	0.01	0.442	1.56 (1.05 to 2.31)	0.03

CE, cardioembolic stroke; EMS, emergency medical services; ER, emergency room; LVD, large vessel disease; NIHSS, National Institute of Health Stroke Scale; SDA, stroke of determined aetiology; SUD, stroke of undetermined aetiology; SVD, small vessel disease; TOAST, Trial of Org 10172 in Acute Stroke Treatment.

associated with higher rates of dysphagia ($p=0.014$) and aspiration pneumonia ($p=0.006$). Similarly, Jeyaseelan *et al*³² demonstrated NIHSS>9 as being moderately predictive of clinically relevant dysphagia, with dysphagia rates increasing with greater NIHSS scores ($p<0.001$). Okubo *et al*³⁴ also showed an NIHSS cut-off of 12 sensitive for dysphagia detection, with 14 (87.5%) of the 16 patients with dysphagia having NIHSS scores ≥ 12 and 2 (12.5%)

patients having scores of 10 and 11. NIHSS>12 also has an independent association with persistent dysphagia at hospital discharge in patients with acute ischaemic stroke with dysphagia at stroke onset, with one of its subcomponents—dysarthria—emerging as a significant independent predictor of prolonged dysphagia.³⁵ In our current study, the odds of developing aspiration pneumonia increased as NIHSS score increased.




Figure 1 Proportion of aspiration pneumonia between stroke ward versus medical ward * $p \leq 0.05$. NIHSS, National Institute of Health Stroke Scale.

Several studies have reported the adverse outcomes of aspiration pneumonia on patients with stroke. In a study comprised of 610 668 patients with stroke, Barlas *et al*³⁶ reported that patients with stroke-associated pneumonia (SAP) had significantly higher odds of in-hospital

mortality (OR of 2.90, 95% CI: 2.83 to 2.96), and longer LOS (OR 13.11, 95% CI: 12.83 to 13.40). While they analysed data from both ischaemic and haemorrhagic strokes, patients with ischaemic stroke were more likely to die in hospital and experience long LOS.³⁶ Teh *et al*³⁷ had similar

Proportion of mRS at 90 days for patients with an NIHSS of 5-9




Figure 2 Proportion of mRS at 90 days for patients with an NIHSS of 5–9. mRS, modified Rankin Scale; NIHSS, National Institute of Health Stroke Scale.

Proportion of mRS at 90 days for patients with an NIHSS of >10




Figure 3 Proportion of mRS at 90 days for patients with an NIHSS of >10. mRS, modified Rankin Scale; NIHSS, National Institute of Health Stroke Scale.

observations in his cohort of 9238 patients from the UK. SAP was found in 1083 (11.7%) patients, out of which 60.8% were aspiration pneumonia.³⁷ After controlling for confounders, SAP was found to be associated with increased mortality up to 1 year (inpatient, 90-day, 1

year), prolonged LOS and poor functional outcome on discharge.³⁷ In our current study, patients who developed aspiration pneumonia with an admission NIHSS of 5–9 had a 16.9% mortality rate at 90 days in contrast to 1.9% for patients who did not develop aspiration pneumonia.




Figure 4 Forest plot based on the results of multivariate analysis of the factors associated with aspiration pneumonia. ER, emergency room; NIHSS, National Institute of Health Stroke Scale; OR, odds ratio; TOAST, Trial of Org 10172 in Acute Stroke Treatment.

Similarly, patients who developed aspiration pneumonia with an admission NIHSS > 10 had higher mortality rates at 90 days (22.3% vs 13.8%, $p=0.003$).

Dysphagia is a common feature of severe stroke and an indicator of poor prognosis. It is implicated in the development of aspiration pneumonia, and it results in longer LOS and increased mortality. In patients with stroke with dysphagia, early nutritional support is vital and the decision to initiate that depends on the outcome of the swallow study.³⁸ Multiple national and international guidelines recommend that people with acute stroke have their swallowing screened by a trained healthcare professional using a validated screening tool and that the patients remain nothing per oral until a swallow screen is performed.¹⁷ Bedside swallow screening tools include the functional bedside aspiration screen, GLOBE-3S (the Sapienza GLOBal Bedside Evaluation of Swallowing after Stroke), water swallowing test, volume-viscosity swallow test and the Gugging swallow screen. However, despite these recommendations, in our study, 34.6% of patients did not undergo swallow screening prior to per os (PO/ by mouth) intake in the ED and 32.7% patient did not have speech language pathologist (SLP) assessment within 24 hours of admission. Likely explanations for these findings include ED nursing inadvertently giving patients PO medications, or SLPs not being available over the weekend, hence leading to an inability to perform assessment within 24 hours of presentation.

Similar to previous reports, we observed a significantly higher risk of aspiration pneumonia in the patients admitted to the medical ward compared with the stroke ward (5.3% vs 3.7%, $p=0.01$). Admission to the stroke ward, by prevention of medical complications, results in reduced LOS, decreased incidence of complications, improved prognosis at discharge and at 90 days (higher % of mRS scores of 0–2).^{39 40} Similarly, in our current study, fewer patients developed aspiration pneumonia if they were admitted to the stroke ward versus medicine ward (3.7% vs 5.3%, $p=0.01$). Multivariable logistic regression identified admission location as an independent predictor of aspiration pneumonia, with patients admitted to the medicine ward having higher risks of developing aspiration pneumonia (aOR 1.56, 95% CI: 1.05 to 2.31). In our study population, we also observed that 19.9% patients with an NIHSS > 10 and admitted to the medicine ward developed aspiration pneumonia in contrast to patients with an NIHSS > 10 and admitted to the stroke ward (9.9%; $p<0.001$). Thus, healthcare providers should be judicious of the placement of their patients with stroke if they would like to reduce the incidence of aspiration pneumonia.

We also observed that patients with small vessel disease or subcortical stroke were less likely to develop aspiration pneumonia in contrast to patients with cardioembolic stroke, large vessel disease, stroke of undetermined aetiology and stroke of determined aetiology. This is consistent with Alberts *et al*'s study, who reported a low occurrence of aspiration in small vessel infarcts compared with those with both large and small vessel

infarcts ($p=0.002$).⁴¹ Similarly, Jitpratoom and Boonyasiri⁴² observed that 40.7% of their patients with cardioembolic stroke developed aspiration pneumonia in contrast to 11.1% for small vessel occlusion. Multivariable logistic regression analysis revealed that type of stroke was an independent predictor of aspiration pneumonia, specifically for large vessel disease, cardioembolic stroke, stroke of determined aetiology and stroke of undetermined aetiology. A potential explanation for this is that patients with small vessel disease have milder stroke symptoms and fewer neurological deficits in contrast to the other stroke subtypes,⁴³ therefore they might have more preserved/control of their facial, palatal and pharyngeal muscles, reducing their risks of developing dysphagia and aspiration pneumonia. However, additional studies are needed to unravel this relationship.

There are several limitations with our study. Our patient sample is comprised of largely Middle Eastern ethnicity (Qatari, Arabs), South Asian and Far Eastern (Asians) (97.7% vs 2.3% for Caucasians), therefore lacks generalisability. We also had missing data for the mRS score at 90 days for 1846 patients (out of 9197). Since Qatar's population is comprised mainly of expatriate workers, it is not possible to collect data for patients who may have moved back to their home country once their work contract ended.

CONCLUSION

This large study in prospectively collected patients with acute stroke identified multiple factors associated with an increased risk of aspiration pneumonia. Patients who developed aspiration pneumonia were older, presented with more severe neurological symptoms and stayed an average of 10 days longer in the hospital compared with patients without aspiration pneumonia. Patients with large vessel disease, cardioembolic stroke, stroke of determined aetiology and stroke of undetermined aetiology were more likely to develop aspiration pneumonia. Patients who were admitted to the medicine ward also had higher odds of developing aspiration pneumonia in contrast to patients admitted to the stroke ward. Our study showed that aspiration pneumonia was associated with an unfavourable prognosis (mRS 3–6) and increased mortality at 90 days in patients with moderate and severe symptoms.

Contributors KHT: Writing—original draft, Formal analysis. NA: Formal analysis, Methodology, Supervision, Reviewing draft. AA: Writing, Reviewing draft. SJ: Data curation and Validation. RTU: Data curation and Validation. DM: Data curation and Validation. BB: Data curation, Methodology. AS: Conceptualisation, reviewing, editing and guarantor.

Funding The authors have not declared a specific grant for this research from any funding agency in the public, commercial or not-for-profit sectors.

Competing interests None declared.

Patient and public involvement Patients and/or the public were not involved in the design, or conduct, or reporting, or dissemination plans of this research.

Patient consent for publication Not applicable.

Ethics approval The studies involving humans were approved by the Institutional Review Board of the Medical Research Centre at Hamad Medical Corporation (MRC-01-18-102). The studies were conducted in accordance with the local legislation

and institutional requirements. Written informed consent from the patients/ participants or patients/ participants' legal guardian/next of kin was not required to participate in this study in accordance with the national legislation and the institutional requirements. Participants gave informed consent to participate in the study before taking part.

Provenance and peer review Not commissioned; externally peer reviewed.

Data availability statement Data are available upon reasonable request.

Supplemental material This content has been supplied by the author(s). It has not been vetted by BMJ Publishing Group Limited (BMJ) and may not have been peer-reviewed. Any opinions or recommendations discussed are solely those of the author(s) and are not endorsed by BMJ. BMJ disclaims all liability and responsibility arising from any reliance placed on the content. Where the content includes any translated material, BMJ does not warrant the accuracy and reliability of the translations (including but not limited to local regulations, clinical guidelines, terminology, drug names and drug dosages), and is not responsible for any error and/or omissions arising from translation and adaptation or otherwise.

Open access This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: <http://creativecommons.org/licenses/by-nc/4.0/>.

ORCID iD

Kim H Tran <http://orcid.org/0000-0002-3665-7296>

REFERENCES

- Chang MC, Choo YJ, Seo KC, *et al*. The Relationship Between Dysphagia and Pneumonia in Acute Stroke Patients: A Systematic Review and Meta-Analysis. *Front Neurol* 2022;13:834240.
- Teasell R, Foley N, Martino R, *et al*. Dysphagia and aspiration following stroke.
- Martino R, Foley N, Bhogal S, *et al*. Dysphagia after stroke: incidence, diagnosis, and pulmonary complications. *Stroke* 2005;36:2756–63.
- Meng PP, Zhang SC, Han C, *et al*. The Occurrence Rate of Swallowing Disorders After Stroke Patients in Asia: A PRISMA-Compliant Systematic Review and Meta-Analysis. *J Stroke Cerebrovasc Dis* 2020;29:105113.
- Takizawa C, Gemmell E, Kenworthy J, *et al*. A Systematic Review of the Prevalence of Oropharyngeal Dysphagia in Stroke, Parkinson's Disease, Alzheimer's Disease, Head Injury, and Pneumonia. *Dysphagia* 2016;31:434–41.
- Avan A, Digaleh H, Di Napoli M, *et al*. Socioeconomic status and stroke incidence, prevalence, mortality, and worldwide burden: an ecological analysis from the Global Burden of Disease Study 2017. *BMC Med* 2019;17:191.
- Cohen DL, Roffe C, Beavan J, *et al*. Post-stroke dysphagia: A review and design considerations for future trials. *Int J Stroke* 2016;11:399–411.
- Banda KJ, Chu H, Kang XL, *et al*. Prevalence of dysphagia and risk of pneumonia and mortality in acute stroke patients: a meta-analysis. *BMC Geriatr* 2022;22:420.
- Son YG, Shin J, Ryu HG. Pneumonitis and pneumonia after aspiration. *J Dent Anesth Pain Med* 2017;17:1–12.
- Hu X, Yi ES, Ryu JH. Aspiration-Related Deaths in 57 Consecutive Patients: Autopsy Study. *PLoS ONE* 2014;9:e103795.
- Makhnevich A, Feldhamer KH, Kast CL, *et al*. Aspiration Pneumonia in Older Adults. *J Hosp Med* 2019;14:429–35.
- Schallom M, Dykeman B, Metheny N, *et al*. Head-of-bed elevation and early outcomes of gastric reflux, aspiration and pressure ulcers: a feasibility study. *Am J Crit Care* 2015;24:57–66.
- Metheny NA. Risk Factors for Aspiration. *J Parenter Enteral Nutr* 2002;26:S26–31.
- Wattila MM, Nyandaiti YW, Balarabe SA, *et al*. Aspiration pneumonia in patients with stroke in Northeast Nigeria. *Int J Stroke* 2013;8:E16.
- Cichero JAY. Age-Related Changes to Eating and Swallowing Impact Frailty: Aspiration, Choking Risk, Modified Food Texture and Autonomy of Choice. *Geriatrics (Basel)* 2018;3:69.
- Katzan IL, Cebul RD, Husak SH, *et al*. The effect of pneumonia on mortality among patients hospitalized for acute stroke. *Neurology (Ecricon)* 2003;60:620–5.
- Eltringham SA, Kilner K, Gee M, *et al*. Impact of Dysphagia Assessment and Management on Risk of Stroke-Associated Pneumonia: A Systematic Review. *Cerebrovasc Dis* 2018;46:99–107.
- Teramoto S. The current definition, epidemiology, animal models and a novel therapeutic strategy for aspiration pneumonia. *Respir Investig* 2022;60:45–55.
- Lidetu T, Muluneh EK, Wassie GT. *IJGM* 2023;Volume 16:1303–15. 10.2147/IJGM.S400420
- Gupte T, Knack A, Cramer JD. Mortality from Aspiration Pneumonia: Incidence, Trends, and Risk Factors. *Dysphagia* 2022;37:1493–500.
- Pacheco-Castilho AC, Vanin G de M, Dantas RO, *et al*. Dysphagia and Associated Pneumonia in Stroke Patients from Brazil: A Systematic Review. *Dysphagia* 2019;34:499–520.
- Imam YZ, Kamran S, Saqqur M, *et al*. Stroke in the adult Qatari population (Q-stroke) a hospital-based retrospective cohort study. *PLoS One* 2020;15:e0238865.
- Hatano S. Experience from a multicentre stroke register: a preliminary report. *Bull World Health Organ* 1976;54:541–53.
- Adams HP Jr, Bendixen BH, Kappelle LJ, *et al*. Classification of subtype of acute ischemic stroke. Definitions for use in a multicenter clinical trial. TOAST. Trial of Org 10172 in Acute Stroke Treatment. *Stroke* 1993;24:35–41.
- Touma L, Filion KB, Sterling LH, *et al*. Stent Retrievers for the Treatment of Acute Ischemic Stroke: A Systematic Review and Meta-analysis of Randomized Clinical Trials. *JAMA Neurol* 2016;73:275–81.
- Brott T, Adams HP Jr, Olinger CP, *et al*. Measurements of acute cerebral infarction: a clinical examination scale. *Stroke* 1989;20:864–70.
- van Swieten JC, Koudstaal PJ, Visser MC, *et al*. Interobserver agreement for the assessment of handicap in stroke patients. *Stroke* 1988;19:604–7.
- MC, Shaw JE, Jones GR, *et al*. Guidance concerning the use of glycated haemoglobin (HbA1c) for the diagnosis of diabetes mellitus. *Medical Journal of Australia* 2015;203:89–90.
- Warusevitane A, Karunatilake D, Sim J, *et al*. Early Diagnosis of Pneumonia in Severe Stroke: Clinical Features and the Diagnostic Role of C-Reactive Protein. *PLoS One* 2016;11:e0150269.
- Green TL, McNair ND, Hinkle JL, *et al*. Care of the Patient With Acute Ischemic Stroke (Posthyperacute and Prehospital Discharge): Update to 2009 Comprehensive Nursing Care Scientific Statement: A Scientific Statement From the American Heart Association. *Stroke* 2021;52:e179–97.
- Akhtar N, Salam A, Kamran S, *et al*. Ethnic variation in acute cerebrovascular disease: Analysis from the Qatar stroke registry. *Eur Stroke J* 2016;1:231–41.
- Jeyaseelan RD, Vargo MM, Chae J. National Institutes of Health Stroke Scale (NIHSS) as An Early Predictor of Poststroke Dysphagia. *PM&R* 2015;7:593–8.
- Garavelli F, Ghelfi AM, Kilstein JG. Usefulness of NIHSS score as a predictor of non-neurological in-hospital complications in stroke. *Medicina Clínica (English Edition)* 2021;157:434–7.
- Okubo P, Fábio SRC, Domenis DR, *et al*. Using the National Institute of Health Stroke Scale to predict dysphagia in acute ischemic stroke. *Cerebrovasc Dis* 2012;33:501–7.
- Kumar S, Doughty C, Doros G, *et al*. Recovery of swallowing after dysphagic stroke: an analysis of prognostic factors. *J Stroke Cerebrovasc Dis* 2014;23:56–62.
- Barlas RS, Clark AB, Bettencourt-Silva JH, *et al*. Pneumonia and Risk of Serious Adverse Outcomes in Hospitalized Strokes in Thailand. *J Stroke Cerebrovasc Dis* 2019;28:1448–54.
- Teh WH, Smith CJ, Barlas RS, *et al*. Impact of stroke-associated pneumonia on mortality, length of hospitalization, and functional outcome. *Acta Neurol Scand* 2018;138:293–300.
- Han TS, Lean ME, Fluck D, *et al*. Impact of delay in early swallow screening on pneumonia, length of stay in hospital, disability and mortality in acute stroke patients. *Eur J Clin Nutr* 2018;72:1548–54.
- Akhtar N, Kamran S, Singh R, *et al*. Beneficial Effects of Implementing Stroke Protocols Require Establishment of a Geographically Distinct Unit. *Stroke* 2015;46:3494–501.
- Tamm A, Siddiqui M, Shuaib A, *et al*. Impact of stroke care unit on patient outcomes in a community hospital. *Stroke* 2014;45:211–6.
- Alberts MJ, Horner J, Gray L, *et al*. Aspiration after stroke: lesion analysis by brain MRI. *Dysphagia* 1992;7:170–3.
- Jitpratoom P, Boonyasiri A. Factors associated with an increased risk of developing pneumonia during acute ischemic stroke hospitalization. *PLoS One* 2024;19:e0296938.
- Grau AJ, Weimar C, Buggle F, *et al*. Risk factors, outcome, and treatment in subtypes of ischemic stroke: the German stroke data bank. *Stroke* 2001;32:2559–66.